TNF alpha antagonist therapy and safety monitoring - 22/06/11

Doi : 10.1016/S1297-319X(11)70001-X

Thao Pham ^1,^⁎ , Hervé Bachelez ², Jean-Marie Berthelot ³, Jacques Blacher ⁴, Yoram Bouhnik ⁵, Pascal Claudepierre ⁶, Arnaud Constantin ⁷, Bruno Fautrel ⁸, Philippe Gaudin ⁹, Vincent Goëb ¹⁰, Laure Gossec ¹¹, Philippe Goupille ¹², Séverine Guillaume-Czitrom ¹³, Eric Hachulla ¹⁴, Isabelle Huet ¹⁵, Denis Jullien ¹⁶, Odile Launay ¹⁷, Marc Lemann ¹⁸, Jean-Francis Maillefert ¹⁹, Jean-Pierre Marolleau ²⁰, Valérie Martinez ²¹, Charles Masson ²², Jacques Morel ²³, Luc Mouthon ²⁴, Stanislas Pol ²⁵, Xavier Puéchal ²⁶, Pascal Richette ²⁷, Alain Saraux ²⁸, Thierry Schaeverbeke ²⁹, Martin Soubrier ³⁰, Anne Sudre ⁹, Tu-Anh Tran ¹³, Manuelle Viguier ², Olivier Vittecoq ¹⁰, Daniel Wendling ³¹, Xavier Mariette ³², Jean Sibilia ³³
¹ Rheumatology Department, CHU Sainte-Marguerite, Marseille
² Dermatology Department, CHU Saint-Louis, Paris
³ Rheumatology Department, CHU Hôtel-Dieu, Nantes
⁴ Cardiology Department, CHU Hôtel-Dieu, Paris
⁵ Department of Gastroenterology, Chronic IBD, and Nutritional Support, CHU Hôpital Beaujon
⁶ Rheumatology Department, CHU Henri Mondor, Créteil
⁷ Rheumatology Department, CHU Purpan, Toulouse
⁸ Rheumatology Department, CHU Pitié-Salpêtrière, Paris
⁹ Rheumatology Department, CHU Grenoble, Grenoble
¹⁰ Rheumatology Department, CHU Bois-Guillaume, Rouen
¹¹ Rheumatology Department, CHU Cochin, Paris
¹² Rheumatology Department, CHU Trousseau, Tours
¹³ Department of Paediatrics and Paediatric Rheumatology, CHU Bicêtre, Le Kremlin-Bicêtre
¹⁴ Internal Medicine Department, CHU Hôpital Claude Huriez, Lille
¹⁵ Pulmonology Department, CHU Pitié-Salpêtrière, Paris
¹⁶ Department of Dermatology and STDs, CHU Edouard Herriot, Lyon
¹⁷ Paris Descartes University, CIC de vaccinologie, Cochin, Pasteur, Paris
¹⁸ Hepatology and Gastroenterology Department, CHU Saint-Louis, Paris
¹⁹ Rheumatology Department, CHU Dijon, Dijon
²⁰ Haematology Department, CHU Amiens-Picardie, Amiens
²¹ Department of Internal Medicine and Clinical Immunology, CHU Hôpital Antoine Béclère, Clamart
²² Rheumatology Department, CHU Angers, Angers
²³ Immunorheumatology Department, CHU Lapeyronie, Montpellier
²⁴ Internal Medicine Department, CHU Cochin, Paris
²⁵ Paris Descartes University – Liver Unit, CHU Cochin, Paris
²⁶ Rheumatology Department, CH Le Mans, Le Mans
²⁷ Rheumatology Department, CHU Lariboisière, Paris
²⁸ Rheumatology Department, CHU Cavale-Blanche, Brest
²⁹ Rheumatology Department, CHU Pellegrin, Bordeaux
³⁰ Rheumatology Department, CHU Gabriel-Montpied, Clermont-Ferrand
³¹ Rheumatology Department, CHU Jean Minjoz, Besançon
³² Rheumatology Department, CHU Bicêtre, Le Kremlin-Bicêtre
³³ Rheumatology Department, CHU Hautepierre, Strasbourg

Corresponding author. Tel.: +33 4 91 38 34 62; fax: +33 4 91 38 38 87.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	171
Iconographies	0
Vidéos	0
Autres	0

The authors and coordinators received fees from Raison de Santé for their work on these fact sheets.

Abstract

Objectives

To develop and/or update fact sheets about TNF⍺ antagonists treatments, in order to assist physicians in the management of patients with inflammatory joint disease.

Methods

1.	selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable;
2.	identification and review of publications relevant to each topic;
3.	development and/or update of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of chronic inflammatory diseases, such as rheumatoid. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Société Francaise de Rhumatologie. Each fact sheet was revised by several experts and the overall process was coordinated by three experts.

Results

Several topics of major interest were selected: contraindications of TNF⍺ antagonists treatments, the management of adverse effects and concomitant diseases that may develop during these therapies, and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points:

1.	in RA and SpA, initiation and monitoring of TNF⍺ antagonists treatments, management of patients with specific past histories, and specific clinical situations such as pregnancy;
2.	diseases other than RA, such as juvenile idiopathic arthritis;
3.	models of letters for informing the rheumatologist and general practitioner;
4.	and patient information.

Conclusion

These TNF⍺ antagonists treatments fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on these therapies. They will be available continuously at www.cri-net.com and updated at appropriate intervals.

Le texte complet de cet article est disponible en PDF.